AKT1 and triple-negative breast carcinoma: The FAKTION data also contrast with the reported activity of capivasertib or ipatasertib (another pan-AKT inhibitor) in combination with paclitaxel in the PAKT22 and LOTUS23 studies in metastatic triple-negative breast cancer.